Spotlight on MRA’s Ninth Annual Scientific Retreat

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 28 February 2017 In Allies & Partnerships, Events, Science

In mid-February, MRA held its premiere research event — the 9th Annual Scientific Retreat, in Washington, DC. A total of 297 individuals registered for the meeting representing a spectrum of key stakeholders in melanoma including academic investigators, pharmaceutical and biotech company representatives, melanoma advocates from various different non-profit organizations, donors and government officials.

Read More


Melanoma Prevention: The Latest Advances & Future Directions

By Pamela Goldsmith, MRA Director of Communications | 28 February 2017 In Events, Policy, Prevention, Science

During my interview with Susan Swetter, MD, Professor of Dermatology,
Stanford University and VA Palo Alto, at the Melanoma Research Alliance Ninth Annual Scientific Retreat in Washington, DC, I inquired about the Panel Discussion she was part of titled: News from the field: What’s going well and what remains to be done?

Read More


MRA’s Young Investigator Program: Bringing New Talent & Novel Ideas for Research Forward

By Pamela Goldsmith, MRA Director of Communications | 28 February 2017 In Events, Science

In February, at the Ninth Annual MRA Scientific Retreat, a Young Investigator Breakfast brought together scores of past and current MRA Young Investigators where I connected with one of MRA’s first young investigators, Dr. Timothy Bullock.

Read More


The Power of Combination Therapies: One Patient’s Road to Remission

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 28 February 2017 In Science, Treatment

Metastatic melanoma can be a devastating diagnosis to receive. Just hearing the word cancer for most is terrifying. While the fear is understandable, today new targeted therapies and immunotherapies are delivering new hope for many.

Read More


Melanoma 2016 — the Year in Review

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 20 January 2017 In News

In the nearly 10 years since MRA’s founding in 2007, there has been extraordinary progress for melanoma. With 11 new treatments approved since 2011, it began to feel like frequent new drug approvals was the current norm.

Read More


Understanding Neoantigens: A Critical Target for Improving Immunotherapy

By Kristen Mueller, Ph.D., MRA Scientific Program Director | 20 January 2017

The approval of eleven new therapies for melanoma since 2011 has led to dramatic changes in how doctors treat melanoma and even more importantly, has led to better outcomes for many patients. Chief among the new therapies are those that target the immune system.

Read More


Melanoma Immunotherapy and Precision Medicine — a Medical Student’s Perspective

By Pooja H. Rambhia, MD Candidate, Case Western Reserve University | 20 January 2017 In Science

Malignant melanoma research has provided the perfect opportunity to explore the intersection of immunotherapy and precision medicine, which has greatly transformed melanoma therapeutics in the last decade.

Read More


Tara's Story

By Pamela Goldsmith, MRA Director of Communications | 20 January 2017 In Melanoma Stories

To say that Tara Miller inspired mixed emotions is to begin to understand her life. The strong-willed survivor, who lost her battle to melanoma in 2014, reflected the contradictions that define an indomitable will to live.

Read More


Parallels between Disease States

By Michael Kaplan, MRA President & CEO | 30 November 2016 In Science

Six months ago I was offered the opportunity to serve as President & CEO of MRA and in July, I officially began. For the past 24 years, I’ve worked in the HIV field and am struck by the many parallels that exist between my past work and melanoma.

Read More


Uncommon Immunotherapy Side Effects

By Louise M. Perkins, Ph.D., MRA Chief Science Officer | 30 November 2016

A recent report in the prestigious New England Journal of Medicine (NEJM), has spawned reports like this one, regarding the risk of death in patients treated with combination checkpoint treatments. The first author of the NEJM story is MRA-funded investigator, Doug Johnson at Vanderbilt.

Read More


Login

×